Novavax Announced 90.4% Overall Efficacy of COVID-19 Vaccine
The American Biotechnology Company Novavax made an announcement on Monday on the efficacy of the COVID-19 Vaccine. It says vaccinated candidates were found to have the efficacy of 90.4% in a Phase 3 trial conducted across the United States and Mexico. According to the company, additional trial analyses are ongoing, and the results will be submitted to peer-reviewed journals for publication.
The trial results are consistent with the efficacy and safety profile the vaccine previously showed in a Phase 3 trial conducted in the United Kingdom, Dr. Geogory Glenn, President of Research and Development for Novavax, told CNN.
He further added- “Different continents, different populations, different viruses floating around, and yet, we still see really good efficacy.”
According to the study conducted in December, 29,960 adults enrolled across 113 and 6 sites in the United States and Mexico. Some participants were given a placebo, and some were administered the Novavax Vaccine in 21 days.
The Novavax Company said- “The vaccine was generally well-tolerated and included some common side-effects like pain at the injection site, lasting for less than three days, fatigue, headache, muscle pain, lasting less than two days”.
There were 77 cases COVID-19 cases during the study, 63 cases were in the people with the placebo group and 14 in the people with vaccination. The company noted that all vaccinated people had a mild infection. There were ten moderate and four severe cases in the placebo group, demonstrating a 100% vaccine efficacy against moderate or severe disease, according to Novanax.
Most cases in the placebo group were found in high-risk people, such as people above 65 years with certain comorbidities or having frequent exposure to COVID-19. As per the study, the company announced the vaccine’s efficacy was 91% in people with high risk.
Novavax’s research also took a close look at the data of 55 of the 77 COVID-19 cases in the study. The company found that the vaccine was 93.2% efficient against variants of concern.
A final analysis of the company, announced in March, showed that the vaccine has overall efficacy of 89.7%, 96.4%, and 86.3% against the original strain and B.1.1.7 variant first identified in the UK.
Novavax, also called NVX-CoV2373, is different from the other three vaccines already in use across America. Novavax said on Monday, it plans to preserve it for emergency use in America in the third quarter of this year and 100 million doses per month will be manufactured to get on the track.
Read Also: Can COVID-19 Vaccination Also Stop Transmission of Virus?